海普瑞

Low-profile couple reaches top of China's rich list with drug IPO

A low-profile Chinese couple has become the country's wealthiest people overnight after an initial public offering that also earned Goldman Sachs a near 200-fold profit on the bank's original $5m investment in the pair's pharmaceutical company.

Li Li and his wife Li Tan's company, Shenzhen Hepalink Pharmaceutical, sold 10 per cent of its shares this week in a Shenzhen-based IPO that values their combined 80 per cent pre-sale stake at around Rmb42.6bn ($6.2bn).

Goldman Sachs invested $4.9m in 2007 to buy a 12.5 per cent stake in Hepalink that is now worth Rmb6.7bn ($975m), a huge return on paper even before the company begins trading on the stock exchange.

您已阅读34%(661字),剩余66%(1290字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×